Primordial Germ Cell Reprogramming by De Miguel, Maria P. et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 3
Primordial Germ Cell Reprogramming
Maria P. De Miguel, Yago Alcaina and
Diego Sainz de la Maza
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.69965
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited. 
Maria P. De Miguel, Yago Alcaina and 
Diego Sainz de la Maza
Additi nal information is avail ble at the end of the chapter
Abstract
Primordial germ cells (PGCs) are the embryonic precursors of the gametes. Thus, they 
are unipotent cells. However, PGCs share some common features with pluripotent stem 
cells. Among them, PGCs show alkaline phosphatase activity and express stage-specific 
embryonic antigens and pluripotency factors Lin28, Oct4, Sox2, and Nanog. Under spe-
cific conditions, they undergo spontaneous reprogramming in vivo. Moreover, they can 
be easily reprogrammed in vitro into pluripotent embryonic germ cells (EGCs) by cultur-
ing them in the presence of basic fibroblast growth factor or the epigenetic modulator 
trichostatin A. Previous work in our laboratory has also proven that hypoxia alone can 
reprogram PGCs into hypoxia-induced embryonic germ-like cells, which have a pluripo-
tent phenotype but which do not show self-renewal capacity. Therefore, PGCs are an 
interesting model to further comprehensively understand the process of cell reprogram-
ming. This chapter reviews various methods to achieve PGC reprogramming, as well as 
the molecular pathways involved. We focus on soluble factors and genetic strategies to 
obtain pluripotent cells from PGCs. Special emphasis will be given to factors implied 
in energetic metabolism, epigenetics, and cell signaling transduction, both in vitro and  
in vivo.
Keywords: cellular reprogramming, ROS, glycolysis, autophagy, primordial germ cells, 
pluripotency, metabolism, hypoxia, epigenetics
1. Introduction
During normal embryogenesis and throughout the life of an organism, cells maintain or 
restrain their developmental potential. This potential refers to the ability to give rise to vari-
ous types of cells. After fertilization, the resulting zygote and the blastomeres are totipotent 
until the four-cell stage, meaning they can develop a complete organism alone, including 
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extraembryonic tissues such as the placenta [1]. Pluripotent stem cells, like embryonic stem 
cells (ESCs), are defined by their potential to differentiate into cells of the three germ layers 
(endoderm, mesoderm, and ectoderm), but they do not give rise to extraembryonic struc-
tures. In a more differentiated state, we find multipotent cells capable of differentiating into 
several types of cells. This capability is common in progenitor cells in adults, which give rise 
to diverse tissue cells.
In some processes, differentiated cells revert to a less differentiated and higher potential state. 
These phenomena are called reprogramming and are shown both in vivo and in vitro. In vivo 
reprogramming can be demonstrated by the appearance of cancer stem cells, and in vitro 
reprogramming has been achieved by several methods, such as somatic cell nuclear trans-
fer, cell fusion between somatic and pluripotent cells, and treatment with pluripotent cell 
extracts, among others [2].
The most important and well-studied method of in vitro reprogramming in the last decade has 
been the derivation of induced pluripotent stem cells (iPSCs) from somatic cells by transduc-
tion of specific transcription factors, Oct4, Sox2, Klf4, and c-Myc [3]. These cells represented a 
revolution in stem cell research because they eliminated the ethical concerns about the use of 
ESCs and allowed access to an endless and personalized source of pluripotent cells. The clini-
cal potential of this discovery is enormous, with the possibility of generating patient-derived 
iPSCs with applications not only in autologous transplants, but also in disease modeling and 
regenerative therapy. The use of iPSCs is extensive, and new ways to improve their derivation 
are being studied to increase efficiency and to overcome the risks for their clinical use. Even 
with the progress that has been made, there is still much to understand about the mechanisms 
of reprogramming.
In the study of pluripotency induction, an important model could be the use of primordial 
germ cells (PGCs), which can give rise to pluripotent cells called embryonic germ cells (EGCs). 
This reprogramming is achieved relatively easily, without the need for gene transduction, 
thus avoiding the risks related to gene manipulation [4–6]. PGCs are the embryonic precur-
sors of gametes, giving rise during normal development to either spermatozoids or oocytes. 
These cells have limited self-renewal ability and are unipotent, are incapable of forming plu-
ripotent embryoid bodies or contributing to teratomas or chimeras [7]. However, PGCs are 
considered developmentally pluripotent, given they generate the whole totipotent zygote 
after fertilization. This dual identity of both differentiated and pluripotent stem cells make 
PGCs a unique model to study cell fate and flexibility.
PGCs suffer reprogramming both in vivo and in vitro. In vivo, PGCs can give rise to embryonal 
carcinoma cells (ECCs), which are the pluripotent stem cells of testicular tumors [7]. In vitro, PGCs 
are easily reprogrammed into pluripotent EGCs with a specific cocktail of growth factors [4].
The reprogramming ability of PGCs can be explained by their similarity to pluripotent cells 
and their latent totipotency. PGCs innately express several transcription factors related to 
pluripotency, such as Oct4, Sox2, Nanog, and Lin28 [7]. Some of these factors are retained 
during PGC development from the zygote, whereas others such as Sox2, Nanog, and Klf2 are 
reexpressed or upregulated [8].
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Other markers, such as tissue nonspecific alkaline phosphatase (TNAP) and germ cell nuclear 
antigen, do not belong to the pluripotency network itself, but are also strongly expressed 
by PGCs and ESCs. Even typical germ line factors such as B lymphocyte-induced matura-
tion protein-1 (Blimp1) and Stella are typically expressed by ESCs [9]. It has been described 
that derivation of ESCs from the inner cell mass (ICM) is preferably achieved from cells that 
express Blimp1 and other germ line markers (interferon-induced transmembrane protein 3, 
Lin28, Prdm14, Stella, & c-Kit) [10]. The similarities in gene expression between PGCs and 
ESCs lead to the idea that the closest in vivo equivalent to ESCs are germ cells, instead of the 
ICM or even the epiblast, because PGC precursors are specified within the epiblast around 6 
days post coitum (dpc) in mice [11].
The proximity of the PGCs to pluripotent stem cells and the ease of their reprogramming 
agree with the results of experiments on iPSC derivation from differently developed cells. 
The more undifferentiated the cells, the more easily they give rise to iPSCs, in a more effi-
cient manner and requiring the transduction of fewer transcription factors. Conversely, the 
more differentiated cells, the more difficult they are to reprogram [12]. PGCs, however, can 
be reprogrammed with the transduction of only one of any of the four traditional iPSC factors 
[13]. This result is especially interesting because PGCs already express Oct4 and Sox2, which 
means that a variation in the expression level of just one transcription factor can be sufficient 
for PGCs to become pluripotent.
2. PGC reprogramming in vivo
ECCs are the stem cells of testicular tumors, which can be maintained indefinitely in culture 
as pluripotent cells. ECCs were first established as cell lines from mouse teratocarcinomas 50 
years ago. In humans, the first teratocarcinoma cell lines isolated in vitro were TERA1 and 
TERA2, but their identity as ECCs was not discovered until some years later [14].
These pluripotent stem cells share most of their characteristics with ESCs, such as self-renewal 
capacity, specific markers, and the ability for differentiation to any cell of the organism [15]. 
The main difference from other pluripotent cells is that they are usually aneuploid. The malig-
nancy of these cells is highly dependent on the microenvironment, as has been observed in 
chimera formation experiments: ECCs injected into mouse blastocysts can contribute to the 
development of a normal chimera, or in some cases to tumors. Another difference from ESCs 
is the very low efficiency in colonizing the germ line, which makes them less suitable for 
establishing mutant rodent lines [2]. Some authors define these cells as multipotent rather 
than pluripotent due to limitations in the differentiation potential, which is even more limited 
in human lines that often show no differentiation potential at all [14]. This potential has not 
been consistent, changing from one ECC line to another, and varying with culture conditions, 
such as the F9 EC line, which was considered nullipotent until the discovery of the induction 
of differentiation by retinoic acid (RA) exposure [16]. Considering the definition of pluripo-
tency as the ability to differentiate into cells of the three germ layers, most ECC lines are plu-
ripotent, but could be considered incompletely or partially pluripotent cells.
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The germ line origin of the ECCs was proven using transgenic Steel (Sl) mutant mice. These 
mice, carrying a homozygous mutation in the Sl locus are unable to express stem cell factor 
(Kit ligand), a growth factor required for PGC survival and proliferation [17]. When embry-
onic gonads of the teratogenic mouse strain 129/Sv are transplanted to the adult testis, tera-
toma formation occurs in wild-type mice but not in Sl mutants, suggesting the Kit ligand is 
implicated in ECCs.
Most ECC lines are derived from early mouse PGCs (8.5–10.5 dpc), and spontaneous terato-
mas have been described to start around 12.5 dpc. PGCs lose their ability to reprogram in vivo 
after 12.5 dpc, which is coincident with the time the PGCs are able to give rise to EGCs in vitro. 
When 129/Sv 12.5 dpc gonads were transplanted into adult testes, teratomas appear at an 80% 
incidence, whereas when 13.5 dpc gonads were grafted, the tumor incidence decreased to 
8%. The induction of these tumors is also related to the strain used, and is far less efficient in 
strains other than 129/Sv [14, 15].
In vivo reprogramming of PGCs to ECCs depends on a variety of genetic factors. The best 
known mutation that affects the development of mice teratomas is Teratoma (Ter) [18] in the 
RNA-modifying gene DND microRNA-mediated repression inhibitor 1 (Dnd1). In homozy-
gous 129/Sv-Ter mice, teratoma incidence increases up to 75%. This reprogramming appears 
to be linked with proliferation, because the PGCs of these mice continue proliferating after 
13.5 dpc, whereas unmutated PGCs enter mitotic arrest. The Ter mutation appears to be 
caused by the surrounding somatic cells instead of the PGCs themselves. In a similar manner, 
doublesex-related transcription factor 1 (Dmrt1) mutants also develop teratomas at a high 
rate in 129/SV mice, but unlike the Ter mutation, this effect is achieved by the loss of Dmrt1 
in PGCs [19, 20].
Also related to PGC transformation is the phosphoinositide-3 kinase (PI3K)/protein kinase B 
(Akt) pathway, whose upregulation could lead to the appearance of ECCs. This outcome can 
be observed in the effect of the specific inactivation in PGCs of the tumor suppressor phospha-
tase and tensin homologue (PTEN), which leads to an activation of PI3K/Akt signaling, and, 
therefore, testicular teratoma formation [21]. Among the Akt targets is the tumor suppressor 
Trp53, whose deletion increases the incidence of testicular teratomas in mice [22].
Testicular cancers in humans are classified into three categories: (1) teratomas and yolk sac 
tumors that develop in fetuses and infants and are classified as nonseminomas, (2) adult tes-
ticular cancer, both seminomas and nonseminomas, which appear in men aged between 20 
and 40 years, and (3) spermatocytic cancer, which affects elderly men [20]. The first two types 
have characteristics in common with mouse carcinomas. Teratomas and yolk sac tumors that 
arise early in human life are the most similar to the teratocarcinomas described in mice, even 
if normal karyotypes are present, and probably also originate from PGCs. With respect to 
adult human testicular tumors, the cellular origin of these tumors is carcinoma in situ, which 
is considered to develop early from the germ line due to the similarity to PGCs and gonocytes. 
Between these similarities, there is the expression of specific membrane markers, such as Kit 
or TNAP; stem and early germ cell genes, such as Nanog or Vasa; and genomic imprinting 
[23]. These cells can remain nonpathological until adult life and later develop into teratomas. 
Unlike the previous type, these cancer cells show chromosomal abnormalities, such as iso-
chromosome of the short arm of the 12th chromosome (iso-12p) [24].
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As in the mouse, the PI3K/Akt pathway is related to teratoma formation in humans. AKT1 
overexpression, Trp53 deficiency and PTEN inactivation, or KRAS and NRAS mutations, 
which lead to activation of this pathway, correlate with testicular cancer formation. The Kit 
signaling pathway can also be implicated in the origin of human ECCs. Both KIT and Kit 
ligand (stem cell factor) mutations are related to human teratomas [19].
In addition, typical reprogramming factors such as Oct4 and Sox2 [3] are related to in vivo 
germ cell reprogramming. The Oct4 expression level appears to affect germ cell reprogram-
ming in vivo, given its reported overexpression in both teratomas and adult testicular cancers 
[25]. On the other hand, Sox2 is only expressed in ECC, but not in PGCs or other testicular 
cancer cells [26].
The appearance of human testicular cancer has also been shown to be related to disturbances 
in the environment of the germ cells in the embryo, and in diseases such as cryptorchidism, 
gonadal dysgenesis, or estrogen exposure during pregnancy [27–29]. Estrogen upregulates 
c-Kit in the genital ridges, which leads to an increased proliferation of PGCs and reprogram-
ming [30, 31].
3. PGC reprogramming in vitro
EGCs are derived in vitro from PGCs when cultured with a specific cocktail of growth factors: 
stem cell factor (SCF), leukemia inhibitory factor (LIF), and basic fibroblast growth factor 
(bFGF) [4, 5, 32]. EGCs are complete pluripotent cells, which are, like ESCs, able to give rise to 
all cell types in the organism and to fully contribute to blastocyst complementation, including 
contributions to the germline transmission [5, 32]. EGCs also share specific markers, such as 
stage-specific embryonic antigens (SSEAs), Oct4, Nanog, and TNAP, with other pluripotent 
stem cells [33].
EGCs were first derived from mice [4, 5] and then from various other animals [34]. EGCs have 
also been derived from human PGCs of around 5–10 weeks of gestation, providing a source 
of pluripotent stem cells and a good model of reprogramming [32].
Contrary to ECCs, EGCs are euploid and the primary difference between them and ESCs 
is the epigenetic state [7]. At the time of reprogramming, PGCs find themselves in different 
phases of the erasure and reestablishment of genomic imprints, and these epigenetic features 
are transmitted to the resulting EGCs. The epigenetic state of the PGCs is related both to the 
maintenance of the latent totipotency and to the inhibition of the stemness [35]. The manipu-
lation of PGC epigenetics has proven the capability of reprogramming to EGCs (as we discuss 
later), showing how close these cells are to pluripotency.
Pluripotent stem cells can be found in various development states, with mouse ESCs rep-
resenting the most undifferentiated, or naïve. This state is characterized by small, compact 
colonies; better survival when passaged as single cells; higher efficiency in chimera formation; 
shorter doubling time; and different culture condition requirements [36]. Human ESCs and 
mouse epiblast stem cells represent the most differentiated or primed state, characterized by 
larger flat colonies [37]. Human EGCs share some of their features with naïve stem cells, such 
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as colony shape and culture requirements, and other features related to a more differentiated 
state, such as the lack of teratoma formation when injected into mice and low efficiency when 
derived from subculture [38]. This outcome shows how close PGCs are to totipotency and 
how useful they can be as a study model. The only major problem for this model is the avail-
ability of PGCs, which are scarce at the time when they are able to reprogram and are difficult 
to expand, because they only survive approximately a week in culture [33].
4. Classical PGC reprogramming mechanism
As we previously explained, PGCs can be cultured with LIF and SCF, maintaining their phe-
notype and promoting their survival for approximately a week [11]. When basic fibroblast 
growth factor (bFGF) is added to the media, reprogramming of the PGCs is induced. The 
mechanisms involved in this process are still not fully understood. Several signaling path-
ways and genes have been shown to be implicated, such as Blimp1 downregulation, PTEN 
inactivation, Klf4, and c-Myc upregulation, PI3K/Akt signaling activation, and transforming 
growth factor (TGF)β signaling, among others [21, 39–41]. Most of these mechanisms are also 
involved in iPSC derivation, indicating a common regulatory network between the various 
reprogramming processes [19].
The dynamics of the transition from a unipotent germ cell to a pluripotent stem cell have been 
studied [42]. Three phases have been described, which are similar to those in iPSC deriva-
tion [43], based on the loss of germ cell characteristics and the expression of pluripotency 
genes: induction, preparation, and maintenance. This change in gene expression is a gradual 
process that takes approximately a week to complete. In the induction phase, along with the 
upregulation of Klf4 and embryonic stem cell-expressed ras (Eras), some germ cell markers, 
such as Dnd1 and Ddx4, start to be downregulated. Surprisingly, a large amount of PGCs 
that begin the reprogramming die in this first step. Some pluripotent factors, such as Klf4 and 
Eras, begin to be upregulated in the early phase, but they do not reach their higher expression 
until later phases, when most pluripotent factors, such as c-Myc and Nanog, are upregulated. 
In the preparation phase, some pluripotent markers, such as Klf4, Nanog, and Zfp42, reach 
their highest expression level, whereas others, such as Klf9 and Sox11, continue their gradual 
upregulation. It is also interesting to notice the high expression in this phase of the Meis fam-
ily of transcription factors, a family related to the maintenance of hematopoietic stem cells.
Compared with PGC reprogramming, the traditional iPSC derivation process is far longer, 
taking approximately 3 weeks to complete. One primary difference between the EGC and 
iPSC derivation processes is that in the latter, a mesenchymal-to-epithelial transition takes 
place in an early phase. The lack of that event in PGC reprogramming could be due to the lack 
of the inverse process (epithelial-to-mesenchymal transition) during PGC specification, which 
is contrary to most somatic cells [8]. Moreover, the activation of genes already expressed in 
PGCs, such as SSEAs or TNAP, takes place in this first phase. The preparation phase is char-
acterized by the upregulation of Nanog (as in EGC derivation), Sall4, and Esrrb. Other genes 
reactivated after these are Rex1, Lin28, and finally, Stella, Dppa4, or Pecam, among others. 
Between the transduced factors, endogenous Oct4 is typical of the preparation phase, whereas 
endogenous Sox2 is necessary for the maintenance phase [8].
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Inhibition of Blimp could be the primary mechanism of bFGF-mediated EGC derivation. 
Blimp is the key germ cell specification gene [44], which has a potent repressive function. 
Among its targets are c-Myc and Klf-4, two of the primary pluripotency transcription factors; 
thus, Blimp inhibition leads to their upregulation [39]. These factors are particularly impor-
tant in the acquisition of pluripotency, and they are the factors not expressed naturally in 
PGCs. It has recently been reported that deletion of Blimp1 in PGCs is sufficient to cause the 
derivation of EGCs in culture without bFGF [45].
5. Non-classical PGC reprogramming
It has been shown that the PI3K/AKT signaling pathway is involved in PGC reprogramming in 
vitro. PI3K is activated not only by bFGF but also by LIF and SCF, the three factors needed for 
EGC derivation. One of its primary downstream effectors is Akt, also known as protein kinase 
B, which has been observed to improve EGC derivation efficiency when activated in PGCs, 
even allowing the reprogramming in late PGCs up to 14.5 dpc. [40]. The specific in vivo inacti-
vation of the tumor suppressor PTEN in PGCs, which leads to PI3K/Akt signaling activation, 
and enhances both EGC derivation and testicular teratoma formation [21]. Among Akt targets 
is the tumor suppressor Trp53. Akt inhibits its transcriptional activity by preventing its phos-
phorylation and nuclear accumulation. Deletion of Trp53 increases the incidence of testicular 
teratomas in mice and is enough to cause PGC reprogramming in culture in the absence of 
bFGF [40]. Trp53 deletion has similar effects on iPSCs, enhancing their induction [46].
The cell proliferation rate also appears to be as important in PGC reprogramming as it is in 
iPSC derivation [47]. The time when PGCs have the highest potential to give rise to EGCs 
coincides with the moment of the highest proliferation in vivo [5]. The three growth factors 
typically used for EGC derivation are mitogens that can alone promote proliferation [48]. Also, 
bFGF can be replaced by other known mitogens, such as RA or forskolin [11, 49], which acti-
vates protein kinase A by increasing the intracellular cyclic AMP. These pro-mitogenic effects 
could be triggered both by MAPK signaling [50] and the PI3K/Akt pathway, which enhances 
proliferation through several downstream effectors. One is by the already mentioned inhibi-
tion of Trp53, but there are others, such as the activation of cyclin D and inhibition of cyclin-
dependent protein kinase inhibitors (CDKIs) [51]. The effects of CDKI inactivation have been 
observed in the mutation of the CDKI inhibitor of CDK4 (INK4), which enhances teratoma 
formation in mice, along with Trp53 inhibition [22].
PGC reprogramming can also be achieved by inhibition of MAPK/extracellular signal-reg-
ulated kinase (ERK), and glycogen synthase kinase-3 (GSK3) signaling. The two inhibitors 
that have been used for this purpose have been PD0325901 (PD) and CHIR99021, respectively 
(named 2i), which in combination with LIF can replace both SCF and bFGF and give rise to 
EGCs [52]. The same inhibitors have been used to enhance iPSC derivation, thus obtaining a 
more undifferentiated phenotype [53]. The mechanism followed by 2i or by bFGF reprogram-
ming differs, because bFGF activates MAPK signaling [54]. It has been proposed that MAPK/
ERK inhibition can lead to pluripotency by promoting long-term self-renewal and inhibiting 
differentiation through downregulation of Lef1. In ESCs, Lef1 promotes differentiation by 
inducing lineage specific genes and suppressing pluripotency gene expression. On the other 
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hand, GSK3 inhibits the Wnt/β-catenin pathway, being responsible for the Tcf3-mediated 
repression of other pluripotency-related genes, such as Sox2, Oct4, Nanog, and Esrrb [55, 56]. 
The difference between the mechanism triggered by bFGF and 2i is also revealed by the tim-
ing of the required compounds, whereas bFGF is only needed during the first 24 h [57, 58], 
continuous culture with 2i is required [52].
Recently, another glycogen synthase kinase 3 (GSK3) inhibitor has been found to achieve EGC 
derivation [41]: kenpaullone, which inhibits not only GSK3, but a wide spectrum of kinases 
such as CDKIs, and is sufficient for late (13.5–14.5 dpc) PGC reprogramming. Also, TGFβR 
inhibition by SB431542 can promote reprogramming in 11.5 dpc PGCs. The fact that these 
treatments have no effect on early PGCs, contrary to bFGF and 2i treatments, underlines the 
differences between the mechanisms that can trigger PGC reprogramming. TGFβ inhibition 
could induce reprogramming through promotion of proliferation [59], reducing MAPK activ-
ity [60], and directing induction of the pluripotency network. TGFβ inhibition can replace 
Sox2 transduction in iPSC generation by inducing Nanog expression [61]. On the other hand, 
the effect of various treatments can be combined to enhance reprogramming efficiency, such 
as TGFβR inhibition with 2i, with an efficiency of 12% [42]; TGF-β inhibition + ERK inhibitor 
(PD) [62], or bFGF + 2i + RA + forskolin, with an efficiency of approximately 20% [48]. This 
outcome shows that various mechanisms can synergize their effects in the reprogramming of 
PGCs. It has also been reported that mutations in genes involved in PGC development, such 
as Dnd1, Pten, and Pgct1, improve EGC derivation efficiency [19].
6. PGCs and hypoxia reprogramming
Recently, we have shown the reprogramming of PGCs cultured in hypoxic conditions with-
out bFGF. The EGCs obtained had proven to be pluripotent, even if they were not completely 
reprogrammed, as shown by their limited proliferation [6].
The positive effects of hypoxia in enhancing reprogramming have been reported in iPSCs 
[63]. These hypoxia effects could be related to the idea of cancer stem cells arising in vivo from 
differentiated cells [64], due to environmental causes.
Hypoxia induces a change in the cell’s energetic metabolism, from oxidative phosphorylation 
to glycolysis. This switch in the metabolism has been shown to be required for reprogramming 
of somatic cells to iPSCs. It has also been observed that the closest the somatic cell metabolism 
is to an ESC, the more efficient the reprogramming [65]. This metabolic change is an active 
process at the beginning of the reprogramming process; it has been shown that the expression 
of glycolytic genes, such as glucose transporter (Glut)1, Hxk2, Pfkm, and lactate dehydroge-
nase A (Ldha), is previous to pluripotency genes [66]. The relationship between stemness and 
glycolytic metabolism has been widely described in the Warburg effect, in which cancer cells 
in normoxia change their metabolism from oxidative phosphorylation to glycolysis [67]. It is 
still not clear whether the stem cell program triggers the metabolic change or whether it is the 
metabolic shift that activates the stem cell program; however, it has been demonstrated that 
these two processes are correlated. Our PGC data clearly supports the second hypothesis [6]; 
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one described mechanism of this hypothesis is the positive feedback between glycolysis and 
the oncogene NF-κB [68].
The induction of PGC pluripotency by hypoxia has been demonstrated to be mediated by 
hypoxia-inducible factors (HIFs), given the inhibition of their degradation by dimethyloxal-
oylglycine mimics the effect of hypoxia in the EGC derivation. This agrees with the improved 
reprogramming efficiency observed in iPSC derivation when a prolonged expression of HIF1 
is forced [69].
HIFs are transcription factors that regulate a large number of downstream effectors under 
hypoxic conditions. Among genes regulated by HIFs are pluripotency genes such as Oct4 and 
c-Myc, regulated by HIF2 or Notch, and ETS-1, regulated by HIF1 [70]. The metabolic switch can 
also be provoked by HIF activation. HIF regulates several metabolism-related genes, promoting 
the expression of glycolytic proteins such as GLUT1 & 3, LDHA, ENO1, aldolase A, phospho-
glycerate kinase 1 (PGK1), glyceraldehyde 3-phosphate dehydrogenase (GAPDH), hexokinase 
1 & 2, phosphofructokinase-2 (PFK2), and phosphofructokinase, liver type (PFKL)[65, 71].
These effects in the metabolism coincide with those provoked by Akt signaling, which is 
consistent with the mechanisms proposed for bFGF-mediated reprogramming of PGCs. Akt 
promotes glycolysis by the inhibition of FoxO transcription factors [51]. In somatic cell repro-
gramming, FoxO1 Akt-dependent phosphorylation enhances both glycolysis and iPSC deri-
vation [72].
The mechanism by which HIFs provoke dedifferentiation in PGCs is partially known. It has 
been shown that the deregulation of Oct4 mediated by HIFs could be directly responsible 
for hypoxia-induced reprogramming [6]. Oct4 is one of the primary components of the plu-
ripotency network; small changes in its expression levels result in great effects on stem cell 
development, promoting both undifferentiated and differentiated states, depending on the 
context [73]. Thus, in addition to the effect of its transduction on iPSC derivation, high levels 
of Oct4 can lead to differentiation and low levels can lead to pluripotency entry, provoking a 
dose-dependent induction of differentiation between mesoderm and trophectoderm in ESCs.
However, pluripotent hypoxia-derived EGCs cannot be passaged long-term, probably due to 
a lack of upregulation of c-Myc and Klf4. Gene expression analysis of these cells suggests that 
they have not reached the stabilization phase of cell reprogramming. Comparing the gene 
expression of these phases with those of hypoxia-derived EGCs has shown that the genes 
typical from initiation and maturation are upregulated; however, those belonging to the sta-
bilization phase, such as Dppa3, Dppa4, Utf1, Eras, Lin28, Sox2, and Dnmt3l, are not [6].
As in 2i-mediated derivation of EGCs, and unlike bFGF, hypoxia is needed continuously to 
provoke PGC reprogramming. This need suggests a mechanism closer to that triggered by 
2i. The relationship between hypoxia and GSK3 inhibition has been demonstrated by the fact 
that HIF1α stabilization depends on an inactive GSK3β pathway [74]. Under long hypoxia 
exposure, HIF1 is downregulated though activation of GSK3β. It has also been reported that 
Akt, which inhibits GSK3β, can upregulate HIFs through mammalian target of rapamycin 
(mTOR) activation [51]. This correlation supports the hypothesis of these two methods of 
PGC reprogramming, hypoxia and 2i, being connected.
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7. Primordial germ cell reprogramming and energetic metabolism
Energetic metabolism has deep implications in germ cell development. As evidence, human 
PGCs show lipid droplets and glycogen accumulations on their cytoplasm in order to obtain 
energy [75].
Gene expression analysis comparing PGCs and EGCs showed no relevant differences in 
expression of pluripotency factors, whereas glycolytic enzymes displayed elevated levels in 
EGCs. This link between metabolism and PGC reprogramming has also been reported in PGCs 
cultured in hypoxia. This process leads to the induction of pluripotency, which is dependent 
on HIF1α stabilization and in turn provokes metabolic reprogramming and Oct4 deregulation 
[6]. Other studies have also observed that low Oct4 expression favors a robust pluripotent 
state in embryonic stem cells or acquisition of pluripotency, whereas high Oct4 levels relate 
to differentiation processes [76, 77]. In addition, Oct4, which remains active in PGCs, partici-
pates in metabolism regulation. In embryonic stem cells, Oct4 can induce hexokinase, pyru-
vate kinase, and pyruvate dehydrogenase (PDH) kinase expression, and the overexpression of 
these enzymes can prevent cell differentiation [78]. This has also been observed in PGCs [6]. In 
fact, when glycolysis is favored at low-oxygen concentrations, an increase in iPSC efficiency, 
and an enhancement of the expression of pluripotency factors via HIF expression are observed. 
Furthermore, iPSC derivation can be achieved in hypoxic conditions using only Oct4 and Klf4 
[63, 79]. As mentioned for the comparison between PGCs and their in vitro pluripotent coun-
terparts, EGCs, metabolism is also involved in the malignant transformation of PGCs into their 
pluripotent partners in vivo, ECCs. In particular, miRNA-regulated expression of enzymes 
involved in glycolytic metabolism contributes to the growth of germ cell tumors [80].
Oxygen levels are closely related to metabolism and potentiality. PGCs cultured in hypoxia 
are reprogrammed toward pluripotent cells and cause an increase in glycolytic genes, while 
they downregulate genes involved in oxidative phosphorylation (OXPHOS) [6]. Abundant 
evidence relates hypoxia to inhibition of oxidative metabolism. Among its effects, hypoxia 
inhibits cytochrome c oxidase and complex II of the electron transport chain. In fact, usage of 
the OXPHOS inhibitor carbonyl cyanide 3-chlorophenylhydrazone (CCCP) induces an upreg-
ulation of Oct4, Nanog, and Sox2 in embryonic stem cells [81]. On the other hand, culture of 
these cells in normoxia upregulates genes involved in differentiation [82, 83].
As previously mentioned, PGCs cultured in hypoxia give rise to pluripotent cells, and this 
process takes place in parallel with a metabolic shift toward glycolysis, which is governed 
by HIF1. Consequently, HIF1 inhibition disrupts PGC reprogramming, and HIF stabiliza-
tion induces reprogramming [6]. HIF1 acts as a link between oxygen levels and metabolic 
phenotype inducing the expression of several genes related to glycolysis, such as glucose 
transporters, hexokinase, pyruvate dehydrogenase kinase 1, and lactate dehydrogenase. In 
fact, PGCs reprogrammed through culture in hypoxia show pyruvate dehydrogenase inhi-
bition and mitochondrial inactivation [6]. Recent work from our laboratory has shown that 
PDH needs to be inhibited to achieve PGC reprogramming. Once the glycolytic profile is 
established under hypoxia, an increase in glycolytic flux through PKM2 activation renders in 
a synergetic effect with hypoxia (Sainz de la Maza et al. [129]).
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Hypoxia can also alter the metabolic profile through mitochondrial mass modification. 
Mitochondria in pre-migratory PGCs are globular and localized around the nucleus. During 
migration, mitochondria increase in number and, when they undergo differentiation, they 
increase their number and size even further, and they acquire a more ovoid shape, further 
developing their cristae [84].
HIF1 inhibits PGC1β and induces mitophagy through Bnip3 upregulation [85]. In fact, 
autophagy is required in the early steps of cell reprogramming [86]. A shift has been reported 
in iPSC derivation from complex, active mitochondrial networks with developed cristae 
in fibroblasts to small, spherical, perinuclear, inactive mitochondria without cristae in plu-
ripotent stem cells [66]. The results from our laboratory have shown that hypoxia-induced 
reprogramming causes a marked increase in Bnip3 expression, an essential gene involved in 
mitophagy. Autophagy takes places during reprogramming and is required for pluripotency 
acquisition (Sainz de la Maza et al. [129]).
Additionally, the Lin28/let7 pathway is crucial in glucose metabolism. In particular, Lin28 
increases glucose uptake and metabolism through PI3K/mTOR activation and is involved 
in the translation of genes related to glycolysis, glucose metabolism, cellular carbohydrate 
metabolism, oxidative metabolism, and mitochondria in human embryonic stem cells [87–89].
Lin28 is also closely related to pluripotency, since it contributes to cell reprogramming and 
is present in the reprogramming cocktail, giving rise to iPSCs [90], and is also capable of 
activating the translation of Oct4 at the post-transcriptional level in human embryonic stem 
cells [91].
Primordial germ cells express Lin28 from 7.5 dpc in mouse PGCs and play a key role in 
Blimp1 expression. Lin28 is an RNA-binding protein that is able to bind the let7 precursor, 
impairing let7 processing. Therefore, miRNA let7 is not synthesized and is not able to inhibit 
Blimp1 translation; Lin28 indirectly stabilizes Blimp1 so PGCs can fulfill their germ cell speci-
fication [44, 92].
8. PGC reprogramming and epigenetics
PGCs undergo profound epigenetic reprogramming during their development [42]. Once 
specified, PGC express Blimp1, which is the master regulator of PGCs responsible for somatic 
program repression and germ cell identity [44]. In order to maintain Blimp1 expression and 
establish germ cell fate, Lin28 acts a negative regulator of let7 [92]. In human PGCs, Blimp1 
is the effector that represses the somatic program, and Sox17 is the determinant transcription 
factor that establishes the germinal fate [93]. A recent study has shown a stable and elevated 
expression of Sox15 in early PGCs, which infers a possible role for this molecule in human 
PGCs as a master regulator, rather than Sox17 [94].
At the onset of specification, PGCs show several epigenetic marks, such as H3K4me2, 
H3K4me3, H3K9ac, H3K9me1, H3K9me2, H3K9me3, H3K27me2, and H3K27me3. However, 
these marks are shared at this time by neighboring, future somatic cells [95]. Once PGC 
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migration begins, PGCs reduce the repressive mark H3K9me2 due to downregulation of the 
enzymes Ehmt1 and Ehmt2. PGCs also reduce DNA methylation by downregulation of the 
DNA methyltransferases Dnmt1, Dnmt3a, and Dnmt3b [8, 96]. Prdm14, an essential partner of 
Blimp1 in mouse germ cell development, and Tcfap2c intervene in this demethylation process 
downregulating Ehmt1, Ehmt2, Dnmt3a, and Dnmt3b. This partnership is also involved in the 
reexpression of transcription factors related to pluripotency, such as Sox2 and Klf2. However, 
Prdm14 is not necessary for human PGC development [97, 98]. PGCs progressively increase 
the repressive mark H3K27me3 via polycomb repressive complex 2 (PRC2) [95].
Later, once PGCs have reached the future gonads, they remove imprinting tags, increase 
H4R3me2 mark, and reactivate the inactive X chromosome in female PGCs [95, 99]. H4R3me2 
modification, which takes place on arginine residues, is catalyzed by Prmt5, an epigenetic 
modulator that binds Blimp1, and exerts its epigenetic modifications until it is translocated 
back to the cytoplasm after E11.5 [100]. Another important event that occurs at this stage is 
major global DNA demethylation. It has been proposed that the vast extent of this DNA mod-
ification infers an active process and expression of the hydroxylase Tet1, the cytidine deami-
nase AID, and genes involved in base excision repair response (BER) have been detected. 
Nucleotide excision repair (NER) does not appear to be involved in PGC demethylation 
because no upregulation in molecules that take part in NER has been detected [101]. Finally, 
PGCs lose histone H1, increase nuclear size, lose chromocenters, reduce the epigenetic marks 
H3K9me3, H3K9me2, H3K27me2, H3K27me3, H3K9ac, and H4R3me2, and also lose nucleo-
somal, noncanonical histone H2a.Z [102, 103]. Blimp1 also induces the expression of Jmjd3 
[104], responsible for removing the repressive epigenetic marks H3K9me2 and H3K9me3. In 
B cells, Blimp1 can also interact with chromatin modifier enzymes such as Kdm1a, a histone 
lysine transferase that catalyzes removal of methyl groups from lysines 4 and 9 of histone 3 
[105]. In contrast to Blimp1, which appears to be essential in the repression of the somatic 
program, its effector Prdm14 contributes to establishing potential pluripotency through Sox2 
upregulation in mouse PGCs, given that Sox2 is absent in human PGCs [97, 106]. Kdm6a is 
the histone demethylase that catalyzes the removal of the mark H3K27me3 during this second 
wave of reprogramming. The disruption of this process leads to an aberrant epigenetic repro-
gramming and loss of pluripotency markers Nanog, Oct4, and SSEA1 [107].
Sex determination begins at approximately E12.5. At this moment, DNA methylation is very 
low both in male and female PGCs [108, 109]. However, settlement of the epigenetic signature 
through DNA methylation occurs differently in male and female germlines. In males, de novo 
DNA methylation starts at around E13.5 and is accomplished before birth. Once methylation 
has been completed, gonocytes undergo vast proliferation and then they enter meiosis at the 
onset of gametogenesis. A disruption of methylation in male germ cells renders infertility 
[110]. In females, de novo methylation starts after birth and is not fulfilled until approximately 
P21 [111]. Oocytes undergo cell cycle arrest in meiotic prophase I, and it is not until ovulation 
that they re-enter meiosis. This coincides with the inability of PGCs to become reprogrammed.
Few studies have been performed on human PGCs, and the majority has focused on later stages 
of epigenetic reprogramming. Among the data available, early gonadal PGCs in humans (6–8 
weeks of gestation) show low H3K9me2 and high H3K27me3 epigenetic markers [112]. Studies 
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on pigs have also reported that changes in H3K9me2 and H3K27me3 markers are previous to 
DNA methylation, as observed in mouse PGC development [113]. Human PGCs also display 
active H3K4me1 and H3K4me3 marks and a peak in H3K9ac from 10 to 13 weeks of gestation. 
DNA showed a hypomethylated status and a loss of imprinting marks from gestation week 
10 onwards. It is noteworthy that Blimp1 is restricted to the nucleus from week 7 to week 12, 
whereas Prmt5 is located in the cytoplasm, showing that there is no Blimp1/Prmt5 association 
in human PGCs [112].
Demethylated human PGCs later recover a methylated status, from week 13 of gestation to 
birth [114]. In addition, human postnatal gonocytes show a different epigenetic pattern from 
E13.5 mouse PGCs. Low levels of H3K9me2 are shared with mouse PGCs, but H3K27me3 
shows low levels in post-migratory PGCs [112]. Also in contrast to mouse PGCs, the H3K9me3 
repressive mark is observed in human gonocytes, as well as increased levels of H3K9ac active 
marks [115, 116]. Mouse PGCs show the lowest methylation at E13.5, when less than 10% of 
cytosines located at CpG islands are methylated [109]. Analyses of global methylation sta-
tus from early stages of development have led to the observation that the ICM maintains its 
methylation status and, consequently, to the hypothesis that the germline is responsible for 
most of the DNA demethylation that takes place during development [117]. Specifically, the 
pattern appears to be a global demethylation during PGC migration, in which specific meth-
ylation marks in CpG islands (CGIs) of PGC-specific genes, CGIs on the X chromosome and 
differentially methylated regions in imprinted genes are conserved. Secondly, a new demeth-
ylation wave occurs when PGCs reach the genital ridges, affecting the previously mentioned 
sequences with epigenetic memory. This process involves both active and passive demethyl-
ation pathways [109]. Specifically, mouse PGCs fall from a 78% of global methylation at the 
epiblast stage to 5% at E11.5 (Figure 1). In human PGCs, demethylation takes place during the 
first 12 weeks of development, falling to 7% of methylation [118].
EGCs and ESCs can be fused to B-cells in order to originate a tetraploid hybrid. Methylation 
analysis has shown that the generated hybrids from EGCs showed lower methylation lev-
els than those generated from ESCs, probably showing some sort of epigenetic memory in 
which EGCs resemble the low methylation status of their precedent PGCs. These hybrids 
eliminate the imprints that were present in ESC cells, suggesting that epigenetic reprogram-
ming in EGCs is dominant over ESCs [119]. As previously mentioned, PGCs eliminate their 
imprinting marks at approximately E11-5. EGCs obtained from E11-5 or later PGCs also show 
demethylated imprinting marks, which cause serious alterations in developing chimeras 
[120, 121]. However, EGCs originated from previous PGCs show a less profound imprinting 
erasure and a more hypomethylated status regulated by Prdm14 when EGCs are cultured in 
the presence of GSK3β and MEK (2i) inhibitors [122, 123]. In fact, EGCs eliminate imprinting 
marks in the genes Igf2, Igf2rr, Dlk1, and H19, among others, which are established shortly 
after PGC specification [124, 125]. EGCs and ESCs also share as a common feature the activa-
tion of both X chromosomes in female cells [126].
PGCs can be reprogrammed into EGCs when cultured in the presence of trichostatin 
A (TSA), an inhibitor of histone deacetylase, in substitution for bFGF, stem cell fac-
tor and LIF [39]. In the case of bFGF, this growth factor needs to be added in the first 
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24 h of culture. Substitution of bFGF by TSA accelerates the kinetics of EGC deriva-
tion, with a quicker downregulation of Blimp1 [39]. As stated in the classical PGC repro-
gramming section, bFGF-induced reprogramming of PGCs causes a downregulation of 
Figure 1. Modifications in DNA methylation during mouse PGC and gamete development. Both male and female 
germ cells share a first phase of epigenetic modifications, in which several processes lead to DNA demethylation and 
histone modifications. This phase corresponds to PGC migration and colonization of genital ridges in the first phase 
and development of gonads in the second. After sex determination, differential methylation is observed among male 
and female germ cells. Whereas male germ cells undergo de novo methylation at E13.5, female germ cells maintain 
hypomethylated status until birth.
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Blimp1, which provokes an upregulation of Klf4, c-Myc, and Dhx38. This downregulation 
does not take place if bFGF is added later than 24 h of culture [39, 45, 127]. In EGC deri-
vation by TSA, Blimp1 is absent in EGCs, whereas expression of Klf4, c-Myc, and Eras is 
detected. In bFGF-induced PGC reprogramming, Blimp1 disappears from PGC after 
48 h [39].
As far as Prmt5 is concerned, this epigenetic modifier stays in the nucleus up to 7 days of cul-
ture, when it translocates from the nucleus to the cytoplasm in EGC colonies. Since Blimp1 binds 
Prmt5 to repress gene expression through H2A/H4R3me2s, contributing to maintaining the 
germ cell phenotype, absence of Blimp1 again appears to be a crucial event in PGC reprogram-
ming. Direct targets of this mentioned repression, such as Dhx38 or c-Myc, are detected a few 
days after a bFGF-induced reprogramming procedure. These events were also observed in TSA-
induced reprogramming of PGCs. [39]. Prmt5 has also been linked to pluripotency in ESCs. Its 
loss disrupts pluripotency and causes differentiation of these cells, where it is located in their 
cytoplasm [128]. Prdm14 is also essential for PGC derivation into EGCs. As previously men-
tioned, Prdm14 is an effector of Blimp1 and is involved in the downregulation of methylation 
enzymes during the first demethylation wave and in the reexpression of pluripotency factors. 
PGCs deficient in Prdm14 are unable to reprogram into EGCs because they cannot downregu-
late the repressive marker H3K9me2 and upregulate the epigenetic marker H3K27me3 via PRC2 
[97]. Recent studies from our laboratory have shown that PRC2 is not involved in hypoxia-
induced PGC reprogramming, whereas addition of histone deacetylase inhibitor valproic acid 
(VPA) is capable of inducing PGC reprogramming (Sainz de la Maza et al. [129]).
It is not surprising that epigenetic modifications relate to potency. Pluripotent stem cells show an 
open conformation of chromatin and active chromatin markers, such as H3K4me and H3K9ac 
[130, 131]. On the other hand, differentiated cells display repressed chromatin markers, such as 
H3K27me. Partially differentiated cells show a bivalent chromatin, with both active and repress-
ing markers. Akt, one of the primary factors related to the reprogramming of PGCs, as noted 
before, also promotes a more active chromatin, mainly by inhibition of Mbd3, a component of 
the nucleosome remodeling deacetylase complex. Mbd3 is important in heterochromatin for-
mation, and its inhibition promotes reprogramming in both EGC and iPSC derivation [19].
Epigenetics is also involved in the derivation of iPSCs. Fibroblast reprogramming can be achieved 
exclusively using soluble factors. In the reprogramming cocktail used by Hou et al [131], some 
epigenetic modifiers were included, such as the histone deacetylase inhibitors (HDACi) sodium 
butyrate and VPA, and the Kdm1a inhibitor tranylcypromine [132]. HDACi are strongly related 
to pluripotency acquisition. VPA has been proven to enhance iPSC generation, and usage of 
HDACi can turn pluripotent colonies with fuzzy edges into typical, compact pluripotent colo-
nies [133–135]. VPA can also eliminate the imprinting marks located at the Dlk1-Dio3 gene clus-
ter [136]. Inhibition of the polycomb complex, responsible for gene repression through DNA 
and histone methylation, results in lower iPSC derivation efficiency, probably because this com-
plex is essential to the repression of the somatic program [137]. However, inhibition of histone 
methyltransferases by using BIX-01294 or inhibition of DNA methyltransferases using 5-azacyti-
dine has been reported to improve iPSC derivation. The usage of BIX-01294 on fibroblasts with 
induced expression of only Oct4 and Klf4 rendered a comparable efficiency to that of using the 
four factors [138, 139]. A deeper understanding of the impact of epigenetics in reprogramming is 
required in order to elucidate the role of chromatin and histone modifications in the acquisition 
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of pluripotency. Further research should be performed regarding the link between pluripotency 
and the germline program. For example, the induction of the expression of Prdm14, which is a 
Blimp1 effector, enhances iPSC derivation from mouse and human fibroblasts [140].
9. Concluding remarks and future directions
Various methods and soluble factors can be used for PGC reprogramming, including the clas-
sical bFGF [4, 5, 7, 141], the deletion of Trp53 [40], the addition of mitogens such as RA [11] or 
forskolin, [49], the inhibition of MAPK/ERK kinase and GSK3 signaling [52], and the addition 
of epigenetic modifiers such as TSA [39] and VPA (Sainz de la Maza et al. [129]). In addition, 
inducers of glycolysis such as hypoxia [6] and manipulation of cell metabolism are able to 
induce pluripotency (Table 1) and partial reprogramming, implicating many cytoplasmic and 
nuclear proteins (Figure 2).
All these data highlight the inherent potency of germ cells, allow for further and detailed 
characterization of the reprogramming process and are useful tools for the identification 
of genes involved in germ cell malignant transformation and the development of testicular 
tumors.
Method Mechanism Age (dpc) Efficiency Laboratory/year
bFGF MAPK and PI3K/
Akt activation
8.5 10/80 Hogan [5] and 
McLaren-Surani 
[58]
Forskolin cAMP agonist 11.5 14.5 ± 3.9/(1/2 
genital ridge)
Nakatsuji [49]
Retinoic acid Mitogen 11.5 12.5 ± 5.2/(1/2 
genital ridge)
Nakatsuji 1996 
[49]
Trichostatin A HDAC inhibitor 8.5 25/80 McLaren-Surani 
[58]
Valproic acid HDAC inhibitor 8.5 ND De Miguel, 
submitted
2i PD0325901 MAPK/ERK 
inhibitor
8.5 9.4% Smith [52]
CHIR99021 GSK3β inhibitor
SB431542 TGFβR inhibition 11.5 2.08/104 Nakano [41]
Kenpaullone GSK3β and CDKs 
inhibitor
13.5 2.27/104 Nakano [41]
Hypoxia HIFs activation 8.5 6.9% De Miguel [6]
Table 1. Comparison of different methods of PGC to EGC reprogramming.
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Abbreviations
2i two inhibitors (PD0325901 and CHIR99021)
BER base excision repair response
bFGF basic fibroblast growth factor
Blimp1 B lymphocyte-induced maturation protein-1
Bnip3 BCL2/adenovirus E1B 19 kDa protein-interacting protein 3
CCCP cyanide 3-chlorophenylhydrazone
CDK4 cyclin-dependent kinase 4
Figure 2. Schematic representation of the external factors (in green), signal transduction molecules (in red or white), and 
processes (in yellow) implicated in PGC reprogramming. Directly inhibited molecules in red. Arrows indicate induction 
and broken lines indicate repression of the pathway. PD: PD0325901; SB: SB431542; CHIR: CHIR99021; RA: retinoic acid; 
VPA: valproic acid; TSA: trichostatin A.
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CDKI cyclin-dependent protein kinase inhibitor
CpG cytosine phosphate guanine
Ddx4 DEAD-Box Helicase 4
Dlk1 delta like non-canonical notch ligand 1
Dmrt1 doublesex-related transcription factor 1
Dnd1 DND microRNA-mediated repression inhibitor 1
Dnmt DNA methyltransferase
dpc days post coitum
Dppa developmental pluripotency associated
ECC embryonal carcinoma cells
EGC embryonic germ cells
Ehmt euchromatin histone methyltransferase
ENO1 enolase 1Erasembryonic stem cell-expressed Ras
ESC embryonic stem cells
Esrrb estrogen-related receptor beta
FoxO forkhead box class O
GAPDH glyceraldehyde 3-phosphate dehydrogenase
Glut glucose transporter
Hand1 heart and neural crest derivatives expressed 1
HDAC histone deacetylase
HIF hypoxia-inducible factor
Hxk2 hexokinase 2
ICM inner cell mass of the blastocyst
iPSC induced pluripotent stem cell
Jmjd Jumonji domain containing
Kdm lysine demethylase
Ldha lactate dehydrogenase A
Lef1 lymphoid enhancer binding factor 1
Mbd3 methyl-CpG binding domain protein 3
MEF mouse embryo fibroblast
Meis myeloid ecotropic viral integration site
mTOR mammalian target of rapamycin
NER nucleotide excision repair
Oct octamer-binding transcription factor
PARP poly(ADP-ribose) polymerase
PDH pyruvate dehydrogenase
Pecam platelet endothelial cell adhesion molecule
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PFK phosphofructokinase
PGC primordial germ cell
PGK1 phosphoglycerate Kinase 1
PKM pyruvate kinase muscle
PRC2 polycomb repressive complex 2
Prmt protein arginine methyltransferases
RA retinoic acid
SCF stem cell factor
SSEA stage-specific embryonic antigen
Tbx3 T-box protein 3
Ter teratoma
TGFβ transforming growth factor β
TNAP tissue non-specific alkaline phosphatase
TSA trichostatin A
Utf undifferentiated embryonic cell transcription factor
VPA valproic acid
Zfp42 zinc finger protein
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